跳至主要内容
临床试验/IRCT201701092639N20
IRCT201701092639N20已完成2 期

Evaluation of efficacy of topiramate alone and topiramate with supplement vitamin D3 on monthly frequency, severity, and disability score of headaches in 5-15 year old migraineur children without vitamin D3 deficiency

Shahid Sadoughi University of Medical Sciences, Yazd, Iran0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
5 years 至 15 years(—)
性别
All

入选标准

  • children aged 5-15 years old; having migraine headache based on International Headache Society Criteria; having one or more headache attack per week; having moderate or severe headache disability; having normal hemoglobin level and mean corpuscular volume (hemoglobin level more than 11.5g/dl and mean corpuscular volume more than 80 fL); having sufficient vitamin D3 level ( more than 30 ng/mL); have not received vitamin D3 combinations within the past two months; not used any migraine preventive therapy. Exclusion criteria: secondary headaches such as epilepsy or other neurologic disorders; irregular drugs usage; discontinuation of drugs usage for more than one week; allergy to topiramat or vitamin D3; vitamin D3 level more than 80 ng/mL.

排除标准

  • 未提供

研究者

发起方
Shahid Sadoughi University of Medical Sciences, Yazd, Iran

相似试验